Group 1: Company Overview - Aohua Pharmaceutical has developed a strong brand presence over 20 years, focusing on children's medicine and modern traditional Chinese medicine [2][3] - The company aims to be a leader in high-quality children's medicine and modern traditional Chinese medicine, with a strategic focus on "variety → brand → category" [2][3] Group 2: Market Position and Strategy - The domestic children's medicine market accounts for only 5% of the overall pharmaceutical industry, while children represent approximately 16.6% of the national population, indicating significant growth potential [6] - Aohua Pharmaceutical is positioned as the largest player in the children's medicine sector, benefiting from a strong brand, extensive sales network, and continuous optimization of operations [6] Group 3: Research and Development - In 2017, Aohua Pharmaceutical invested 104 million yuan in R&D, with plans to adjust future investments based on ongoing projects [5] - Key R&D projects include: - Pediatric cough syrup, which is undergoing efficacy trials for additional indications [3][4] - Pediatric anti-cold granules, based on traditional Chinese medicine, with clinical studies already initiated [4] - Liver protection tablets, expanding indications to include drug-induced liver injury and alcoholic liver disease [4] Group 4: Future Growth and Product Development - The company plans to maintain a focus on children's medicine as a key profit growth area, with a product strategy that includes a diverse range of categories [3][5] - Aohua Pharmaceutical will continue to enhance its core brands while also investing in new drug development, ensuring a balanced approach to growth [5][6]
葵花药业(002737) - 2018年7月20日投资者关系活动记录表